Physiology and endocrinology symposium: FGF21: Insights into mechanism of action from preclinical studies

Journal of Animal Science

Volumn 92, Issue 2, 2014, Pages 407-413

  Antonellis, P J ^a   Kharitonenkov, A ^a   Adams, A C ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Adiponectin; Adipose; Beta klotho; Fibroblast growth factor 21; Fibroblast growth factor receptor isoform 1; Leptin

Indexed keywords

FGFR1 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR RECEPTOR 1; KLB PROTEIN, MOUSE; MEMBRANE PROTEIN;

ADIPOSE TISSUE; ANIMAL; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GENETICS; HOMEOSTASIS; KNOCKOUT MOUSE; METABOLISM; MOUSE; PHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; ENERGY METABOLISM; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HOMEOSTASIS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1;

EID: 84893643263     PISSN: 00218812     EISSN: 15253163     Source Type: Journal    
DOI: 10.2527/jas.2013-7076     Document Type: Article

References (47)

1. Adams, A. C., C. C. Cheng, T. Coskun, and A. Kharitonenkov. 2012a. FGF21 requires betaklotho to act in vivo. PLoS ONE 7:e49977.
2. Adams, A. C., T. Coskun, A. R. Rovira, M. A. Schneider, D. W. Raches, R. Micanovic, H. A. Bina, J. D. Dunbar, and A. Kharitonenkov. 2012b. Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS ONE 7:e38438.
3. Adams, A. C., and A. Kharitonenkov. 2013. FGF21 drives a shift in adipokine tone to restore metabolic health. Aging 5:386-387.
4. Adams, A. C., T. Coskun, C. C. Cheng, L. S. O'Farrell, S. L. DuBois, R. E. Gimeno, and A. Kharitonenkov. 2013a. Fibroblast Growth Factor 21 is not required for the antidiabetic actions of thiazolidinediones. Molecular Metabolism 2:205-214.
5. Adams, A. C., C. A. Halstead, B. C. Hansen, A. R. Irizarry, J. A. Martin, S. R. Myers, V. L. Reynolds, H. W. Smith, V. J. Wroblewski, and A. Kharitonenkov. 2013b. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS ONE 8:e65763.
6. Adams, A. C., C. Yang, T. Coskun, C. C. Cheng, R. E. Gimeno, Y. Luo, and A. Kharitonenkov. 2013c. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Molecular Metabolism 2:31-37.
7. Badman, M. K., A. Koester, J. S. Flier, A. Kharitonenkov, and E. Maratos-Flier. 2009. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150:4931-4940.
8. Camacho, R. C., P. T. Zafian, J. Achanfuo-Yeboah, A. Manibusan, and J. P. Berger. 2013. Pegylated FGF21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice. Eur. J. Pharmacol. 715:41-45.
9. Chartoumpekis, D. V., I. G. Habeos, P. G. Ziros, A. I. Psyrogiannis, V. E. Kyriazopoulou, and A. G. Papavassiliou. 2011. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol. Med. 17:736-740.
10. Coskun, T., H. A. Bina, M. A. Schneider, J. D. Dunbar, C. C. Hu, Y. Chen, D. E. Moller, and A. Kharitonenkov. 2008. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018-6027.
11. Ding, X., J. Boney-Montoya, B. M. Owen, A. L. Bookout, K. C. Coate, D. J. Mangelsdorf, and S. A. Kliewer. 2012. betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 16:387-393.
12. Dutchak, P. A., T. Katafuchi, A. L. Bookout, J. H. Choi, R. T. Yu, D. J. Mangelsdorf, and S. A. Kliewer. 2012. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 148:556-567.
13. Fisher, F. M. 2012. FGF21 regulates PGC-1[alpha] and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 26:271-281.
14. Fisher, F. M., J. L. Estall, A. C. Adams, P. J. Antonellis, H. A. Bina, J. S. Flier, A. Kharitonenkov, B. M. Spiegelman, and E. Maratos-Flier. 2011. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 152:2996-3004.
15. Fisher, F. M., S. Kleiner, N. Douris, E. C. Fox, R. J. Mepani, F. Verdeguer, J. Wu, A. Kharitonenkov, J. S. Flier, E. Maratos-Flier, and B. M. Spiegelman. 2012. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 26:271-281.
16. Gaich, G., J. Y. Chien, H. Fu, L. C. Glass, A. Kharitonenkov, T. Bumol, H. K. Schilske, and D. E. Moller. 2013. Effects of a fibroblast growth factor 21 analog, LY2405319, in obese human subjects with type 2 diabetes; results of a randomized proof-ofconcept trial. Cell Metab. 18:333-340.
17. Hager, T., C. Spahr, J. Xu, H. Salimi-Moosavi, and M. Hall. 2013. Differential enzyme-linked immunosorbent assay and ligandbinding mass spectrometry for analysis of biotransformation of protein therapeutics: Application to various FGF21 modalities. Anal. Chem. 85:2731-2738.
18. Holland, W. L., A. C. Adams, J. T. Brozinick, H. H. Bui, Y. Miyauchi, C. M. Kusminski, S. M. Bauer, M. Wade, E. Singhal, C. C. Cheng, K. Volk, M. S. Kuo, R. Gordillo, A. Kharitonenkov, and P. E. Scherer. 2013. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 17:790-797.
19. Hondares, E., M. Rosell, F. J. Gonzalez, M. Giralt, R. Iglesias, and F. Villarroya. 2010. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab. 11:206-212.
20. Hotta, Y., H. Nakamura, M. Konishi, Y. Murata, H. Takagi, S. Matsumura, K. Inoue, T. Fushiki, and N. Itoh. 2009. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 150:4625-4633.
21. Huang, Z., H. Wang, M. Lu, C. Sun, X. Wu, Y. Tan, C. Ye, G. Zhu, X. Wang, L. Cai, and X. Li. 2011. A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol. PLoS ONE 6:e20669.
22. Inagaki, T., V. Y. Lin, R. Goetz, M. Mohammadi, D. J. Mangelsdorf, and S. A. Kliewer. 2008. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 8:77-83.
23. Ito, S., S. Kinoshita, N. Shiraishi, S. Nakagawa, S. Sekine, T. Fujimori, and Y. I. Nabeshima. 2000. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech. Dev. 98:115-119.
24. Itoh, N. 2010. Hormone-like (endocrine) Fgfs: Their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res. 342:1-11.
25. Izumiya, Y., H. A. Bina, N. Ouchi, Y. Akasaki, A. Kharitonenkov, and K. Walsh. 2008. FGF21 is an Akt-regulated myokine. FEBS Lett. 582:3805-3810.
26. Johnson, C. L., J. Y. Weston, S. A. Chadi, E. N. Fazio, M. W. Huff, A. Kharitonenkov, A. Koester, and C. L. Pin. 2009. Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology 137:1795-1804.
27. Jonker, J. W., J. M. Suh, A. R. Atkins, M. Ahmadian, P. Li, J. Whyte, M. He, H. Juguilon, Y. Q. Yin, C. T. Phillips, R. T. Yu, J. M. Olefsky, R. R. Henry, M. Downes, and R. M. Evans. 2012. A PPARgamma-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485:391-394.
28. Kharitonenkov, A. 2009. FGFs and metabolism. Curr. Opin. Pharmacol. 9:805-810.
29. Kharitonenkov, A., J. M. Beals, R. Micanovic, B. A. Strifler, R. Rathnachalam, V. J. Wroblewski, S. Li, A. Koester, A. M. Ford, T. Coskun, J. D. Dunbar, C. C. Cheng, C. C. Frye, T. F. Bumol, and D. E. Moller. 2013. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS ONE 8:e58575.
30. Kharitonenkov, A., J. D. Dunbar, H. A. Bina, S. Bright, J. S. Moyers, C. Zhang, L. Ding, R. Micanovic, S. F. Mehrbod, M. D. Knierman, J. E. Hale, T. Coskun, and A. B. Shanafelt. 2008. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J. Cell. Physiol. 215:1-7.
31. Kharitonenkov, A., and P. Larsen. 2011. FGF21 reloaded: Challenges of a rapidly growing field. Trends Endocrinol. Metab. 22:81-86.
32. Kharitonenkov, A., T. L. Shiyanova, A. Koester, A. M. Ford, R. Micanovic, E. J. Galbreath, G. E. Sandusky, L. J. Hammond, J. S. Moyers, R. A. Owens, J. Gromada, J. T. Brozinick, E. D. Hawkins, V. J. Wroblewski, D. S. Li, F. Mehrbod, S. R. Jaskunas, and A. B. Shanafelt. 2005. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115:1627-1635.
33. Kharitonenkov, A., V. J. Wroblewski, A. Koester, Y. F. Chen, C. K. Clutinger, X. T. Tigno, B. C. Hansen, A. B. Shanafelt, and G. J. Etgen. 2007. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774-781.
34. Kurosu, H., and M. Kuro-o. 2008. The Klotho gene family and the endocrine fibroblast growth factors. Curr. Opin. Nephrol. Hypertens. 17:368-372.
35. Lin, Z. 2013. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 17:779-789.
36. Mu, J., J. Pinkstaff, Z. Li, L. Skidmore, N. Li, H. Myler, Q. Dallas-Yang, A. M. Putnam, J. Yao, S. Bussell, M. Wu, T. C. Norman, C. G. Rodriguez, B. Kimmel, J. M. Metzger, A. Manibusan, D. Lee, D. M. Zaller, B. B. Zhang, R. D. Dimarchi, J. P. Berger, and D. W. Axelrod. 2012. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 61:505-512.
37. Nishimura, T., Y. Nakatake, M. Konishi, and N. Itoh. 2000. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 1492:203-206.
38. Ogawa, Y., H. Kurosu, M. Yamamoto, A. Nandi, K. P. Rosenblatt, R. Goetz, A. V. Eliseenkova, M. Mohammadi, and M. Kuro-o. 2007. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. USA 104:7432-7437.
39. Tomiyama, K., R. Maeda, I. Urakawa, Y. Yamazaki, T. Tanaka, S. Ito, Y. Nabeshima, T. Tomita, S. Odori, K. Hosoda, K. Nakao, A. Imura, and Y. Nabeshima. 2010. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc. Natl. Acad. Sci. USA 107:1666-1671.
40. Turer, A. T., and P. E. Scherer. 2012. Adiponectin: Mechanistic insights and clinical implications. Diabetologia 55:2319-2326.
41. Veniant, M. M., R. Komorowski, P. Chen, S. Stanislaus, K. Winters, T. Hager, L. Zhou, R. Wada, R. Hecht, and J. Xu. 2012. Longacting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 153:4192-4203.
42. Wang, H., L. Qiang, and S. R. Farmer. 2008. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol. Cell. Biol. 28:188-200.
43. Xu, J., G. Gontier, Z. Chaker, P. Lacube, J. Dupont, and M. Holzenberger. 2013. Longevity effect of IGF-1R mutation depends on genetic background-specific receptor activation. Aging Cell 21:1-10.
44. Yang, C., C. Jin, X. Li, F. Wang, W. L. McKeehan, and Y. Luo. 2012. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS ONE 7:e33870.
45. Yie, J., R. Hecht, J. Patel, J. Stevens, W. Wang, N. Hawkins, S. Steavenson, S. Smith, D. Winters, S. Fisher, L. Cai, E. Belouski, C. Chen, M. L. Michaels, Y. S. Li, R. Lindberg, M. Wang, M. Veniant, and J. Xu. 2009. FGF21 N-and C-termini play different roles in receptor interaction and activation. FEBS Lett. 583:19-24.
46. Zhang, X., O. A. Ibrahimi, S. K. Olsen, H. Umemori, M. Mohammadi, and D. M. Ornitz. 2006. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 281:15694-15700.
47. Zhang, Y., Y. Xie, E. D. Berglund, K. C. Coate, T. T. He, T. Katafuchi, G. Xiao, M. J. Potthoff, W. Wei, Y. Wan, R. T. Yu, R. M. Evans, S.A. Kliewer, and D. J. Mangelsdorf. 2012. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. eLife 1:e00065.